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Abstract
Background: Symptoms in hypertrophic cardiomyopathy (HC) appear to be caused by diastolic
dysfunction, myocardial ischemia, left ventricle (LV) outflow obstruction, and atrial fibrillation.
However, clinical deterioration and severe heart failure symptoms can be observed in patients
without any of these factors. Thus, the aim of this study is to determine the echocardiographic
predictors of severe heart failure symptoms in patients with HC.
Methods and results: 86 HC patients were compared according to symptomatic status. Patients
with severe heart failure symptoms were older, preponderantly female, had more often LV outflow
obstruction and mitral regurgitation, longer E wave deceleration time (EDt), higher E/Ea ratios and
lower LV tissue Doppler (TD) velocities when compared to rest of the patients. LV outflow
obstruction (r = 0.43, R2 = 0.19, p < 0.0001), LV lateral mitral annular systolic TD velocity (LMSa)
(r = 0.51, R2 = 0.26, p < 0.006) and EDt (r = 0.55, R2 = 0.30, p < 0.027) were found to be the
independent predictors for severe heart failure symptoms in forward stepwise regression.
Conclusion: In HCM patients with sinus rhythm and normal LV systolic function, LMSa, EDt and
LV outflow obstruction are independent predictors of heart failure symptoms. Diastolic
dysfunction determined with EDt, occult systolic dysfunction which is detected with TD analysis,
and afterload increase as result of LV outflow obstruction seem to be the main echocardiographic
factors affecting symptomatic status in HCM patients with sinus rhythm and normal systolic
function.
Background
Hypertrophic cardiomyopathy (HC) is a complex genetic
cardiac disorder with heterogeneous clinical course and
expression [1-3]. Exertional dyspnea and disability usu-
ally occur in the presence of preserved systolic function
and a non-dilated left ventricle (LV) [1,4]. Symptoms
appear to be caused in large measure by diastolic dysfunc-
tion [5-8], myocardial ischemia [9-15], outflow obstruc-
tion associated with mitral regurgitation [16,17] and atrial
fibrillation [18]. Of these parameters, which predicts heart
failure symptoms best is unclear. Besides, clinical deterio-
ration may be observed even in HC patients without any
of these factors [1,2]. Thus, the aim of this study is to
determine the echocardiographic predictors of severe
heart failure symptoms in patients with HC.
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Methods
Study population
One hundred and ten consecutive patients who were
admitted to our echocardiography laboratory and diag-
nosed as HC were included in the study. The diagnosis of
HC was based on the demonstration of a hypertrophied,
non-dilated left ventricle (LV) (wall thickness of at least
15 mm) by 2-dimensional echocardiography in the
absence of another cardiac or systemic disease capable of
producing a similar degree of hypertrophy [3]. A detailed
clinical evaluation was performed for each patient after
the echocardiographic examination.
Functional capacity was assessed according to the New
York Heart Association (NYHA) classification by one
investigator without knowledge of the laboratory results.
Heart failure symptoms are defined by exertional dyspnea
and functional limitation (with or without chest pain)
independent of whether episodes of impaired conscious-
ness (syncope or presyncope) have occurred [19,20]. Ten
patients with co-morbid cardiovascular, pulmonary, renal
conditions and 14 patients with LV systolic dysfunction
(LV ejection fraction < 50%), previous septal myectomy,
previous alcohol septal ablation and atrial fibrillation
were excluded from the study (remaining 86 patients
formed the study population). The study complies with
the Declaration of Helsinki, was approved by the local
ethical committee and each patient gave written informed
consent.
Echocardiographic analysis
A complete echocardiographic examination was per-
formed with a Vivid Five System (GE, Vingmed Ultra-
sound, Horten, Norway) in each patient at rest by a single
blinded observer. LV hypertrophy was assessed with 2-
dimensional echocardiography according to published
criteria [3]. The greatest thickness measured at any site in
the LV wall was considered to represent LV maximal wall
thickness [21]. Peak instantaneous LV outflow gradient
was estimated under basal conditions with continuous
wave Doppler [17].
2-dimensional measurements included LV end-diastolic
and end-systolic diameters, posterior wall thickness, inter-
ventricular septal thickness, and LV ejection fraction [22].
Mitral inflow Doppler was measured in standard fashion
to determine peak E- and A-wave velocities, deceleration
time of the transmitral E wave, and isovolumic relaxation
time [23]. Mitral regurgitation was assessed by color Dop-
pler velocity mapping as the ratio of the area of the color
jet divided by the maximum LA area [24]. Apical 4-cham-
ber views of color 2-dimensional tissue Doppler (TD)
images were acquired during end-expiration at a frame
rate of 100 to 140 frames per second to minimize back-
ground noise. TD digital data were stored and analyzed
offline (EchoPac, GE Vingmed). Sample volumes were
placed in the inner half of the myocardium on the basal
segments of the left ventricle at the septal, lateral walls and
of the right ventricle at the lateral wall adjacent to the
atrio-ventricular valve hinge points in the apical 4-cham-
ber view [25]. Systolic (Sa), early diastolic (Ea), and late
diastolic (Aa) TD velocities were measured for all seg-
ments and subsequently averaged over 3 cardiac cycles in
accordance with previous reports [23,25]. Transmitral E/
Ea ratios of LV (lateral and septal) were calculated for each
patient.
Statistical analysis
Statistical analysis was performed with SPSS 11.5 (SPSS,
Chicago, Illinois, USA) software. Data are expressed as
mean ± SD. Relevant relationships were tested by χ2 anal-
ysis for proportions and unpaired Student's t test for con-
tinuous variables. For comparison of continuous
echocardiographic variables in different NYHA functional
classes, one way analysis of variance (ANOVA) was used.
Forward stepwise regression was performed to determine
predictors of severe heart failure symptoms. A probability
value < 0.05 was required for retention within the final
stepwise regression model. Statistical significance was
taken as p < 0.05.
Results
Patient characteristics
The pattern of LV hypertrophy was asymmetric septal in
76 patients, apical in 4 patients, concentric in 5 patients
and isolated posterior wall hypertrophy in 1 patient.
Forty-three patients (50%) had basal resting left ventricu-
lar outflow tract obstruction with a peak gradient > 30
mmHg. Thirty patients had a positive family history of HC
(36%) and 18 patients had a history of sudden death in
first degree relatives (22%). At admission 32 (37%) of the
patients were asymptomatic (NYHA class I), 37 (43%)
had mild symptoms (NYHA class II) and 17 (20%) had
severe symptoms (NYHA class III-IV).
NYHA class of patients correlated with various echocardi-
ographic and clinical parameters such as age (p = 0.02, R:
0.34), left atrium diameter (p = 0.04, R: 0.22), E wave
deceleration time (p = 0.001, R: 0.41), LV outflow
obstruction (p = 0.001, R: 0.37), and LV lateral mitral
annular systolic tissue Doppler velocity (LMSa) (p =
0.001, R: -0.36).
The comparison of demographic and echocardiographic
parameters including TD velocities of HC patients with
and without severe heart failure symptoms (NYHA class I-
II vs. NYHA class III-IV) is presented in Table 1. Patients
with severe heart failure symptoms were older, prepon-
derantly female, had more often LV outflow obstruction
and mitral regurgitation, longer isovolumetric relaxationTrials 2008, 9:11 http://www.trialsjournal.com/content/9/1/11
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times, higher E/Ea ratios and lower TD velocities of LV
when compared to patients without heart failure symp-
toms. Medical therapies of the patients with and without
severe heart failure symptoms were similar.
Predictors of severe heart failure symptoms
Table 2 shows the results of univariate and multivariable
analyses for prediction of severe heart failure symptoms.
LV outflow obstruction (r = 0.43, R2 = 0.19, p < 0.0001),
LV lateral mitral annular systolic tissue Doppler velocity
(LMSa) (r = 0.51, R2 = 0.26, p < 0.006) and E wave decel-
eration time (EDt) (r = 0.55, R2 = 0.30, p < 0.027) were
found to be the independent predictors for severe heart
failure symptoms in forward stepwise regression.
LMSa correlated with various echocardiographic and clin-
ical parameters such as left atrium diameter (p = 0.004, R:
-0.30), maximal wall thickness (p = 0.001, R: -0.36), and
NYHA functional class (p = 0.001, R: -0.36).
Table 1: Comparison of demographic, clinical and echocardiographic variables of HC patients with and without severe heart failure 
symptoms (NYHA class I-II vs. NYHA class II-IV)
Variable Severe symptom + (n = 17) Severe symptom – (n = 69) p
Demographics
Female gender 10 (59%) 17 (25%) 0.003
Age (years) 54 ± 17 43 ± 16 0.03
Blood pressure, mmHg 116/67 114/67 NS
Medical therapy
Beta-blockers 14 (86%) 57 (84%) NS
Calcium channel blockers 2 (13%) 10 (15%) NS
Echocardiographic findings
Left atrium, mm 46 ± 6 44 ± 8 NS
LV end-diastolic diameter, mm 38 ± 8 42 ± 5 NS
LV end-systolic diameter, mm 21 ± 5 24 ± 5 NS
Maximal wall thickness, mm 25 ± 6 24 ± 5 NS
Posterior wall diastolic thickness, mm 16 ± 9 13 ± 5 NS
Mitral E velocity, m/s 0.72 ± 0.2 0.77 ± 0.2 NS
Mitral A velocity, m/s 0.88 ± 0.3 0.80 ± 0.3 NS
E deceleration time, ms 267 ± 61 212 ± 76 0.004
IVRT, ms 113 ± 29 108 ± 30 NS
LV ejection fraction, (%) 75 ± 10 76 ± 8 NS
LV outflow obstruction, n (%) 16 (82%) 29 (42%) 0.0001
Tissue Doppler velocities
E/Ea (septal) 33 ± 24 24 ± 17 0.03
E/Ea (lateral mitral) 33 ± 32 18 ± 16 0.004
Lateral mitral Ea, cm/s 3.2 ± 1.4 4.5 ± 2.5 0.007
Lateral mitral Aa, cm/s 4.0 ± 2.3 5.4 ± 2.9 0.05
Lateral mitral Sa, cm/s 3.1 ± 1.4 4.7 ± 1.9 0.001
Septal mitral Ea, cm/s 2.8 ± 1.5 3.5 ± 1.9 NS
Septal mitral Aa, cm/s 4.7 ± 1.9 5.5 ± 1.9 NS
Septal mitral Sa, cm/s 3.7 ± 1.3 4.5 ± 1.4 0.03
Lateral tricuspid Ea, cm/s 6.7 ± 2.5 7.7 ± 3.0 NS
Lateral tricuspid Aa, cm/s 8.8 ± 3.5 10.0 ± 3.8 NS
Lateral tricuspid Sa, cm/s 9.7 ± 1.9 10.2 ± 3.1 NS
IVRT indicates isovolumetric relaxation time; LV, left ventricle, NS; non significant.
Severe symptom + is used for NYHA class III-IV patients, severe symptom – for NYHA class I-II patients.
Table 2: Univariate and multivariate relations for prediction of 
heart failure symptoms
Univariate Multivariable
F value p R2 wald p
Age 5.79 0.018 ... ... NS
Female gender 7.13 0.009 ... ... NS
LV outflow obstruction 18.5 0.0001 0.19 9.1 0.0001
Mitral regurgitation 15.4 0.0001 ... ... NS
Left atrium diameter 1.3 0.25 ... ... NS
Maximum wall thickness 0.3 0.50 ... ... NS
E wave deceleration time 7.1 0.009 0.30 4.7 0.027
Lateral mitral Ea, cm/s 4.1 0.045 ... ... NS
Lateral mitral Aa, cm/s 3.2 0.07 ... ... NS
Lateral mitral Sa, cm/s 8 0.006 0.26 6.3 0.006
Septal mitral Sa, cm/s 4.1 0.045 ... ... NS
E/Ea (septal) 3.7 0.05 ... ... NS
E/Ea (lateral mitral) 6.4 0.01 ... ... NS
LV indicates left ventricle; NS, non-significantTrials 2008, 9:11 http://www.trialsjournal.com/content/9/1/11
Page 4 of 6
(page number not for citation purposes)
EDt correlated with age (p = 0.01, R: 0.27), NYHA func-
tional class (p = 0.0001, R: 0.39), isovolumetric relaxation
time (p = 0.02, R: 0.26).
EDt gets longer (188 ± 55 ms for class I vs. 233 ± 86 ms
for class II vs. 267 ± 61 ms class III-IV, p < 0.001) and
LMSa decreases (5.1 ± 2.0 cm/s for class I vs. 4.3 ± 1.7 cm/
s for class II vs. 3.1 ± 1.4 cm/s class III-IV, p < 0.002) with
increasing NYHA functional class (Figures 1 and 2).
Effect of LV outflow obstruction on demographic and 
echocardiographic variables
HC patients with LV outflow obstruction had significantly
smaller left ventricle cavities, thicker posterior walls, larger
left atrium diameters, longer E wave deceleration times,
more often mitral regurgitation and more often severe
heart failure symptoms than patients without obstruction.
TD velocities of left and right ventricle tended to be lower
in HC patients with LV outflow obstruction when com-
pared to patients without obstruction, but that did not
reach statistical significance (except lateral mitral Ea).
In 43 patients without LV outflow obstruction, only three
patients had severe heart failure symptoms. Severely
symptomatic non-obstructive patients had significantly
larger left atrium diameters (5.1 ± 0.3 cm vs. 4.1 ± 0.6 cm,
p < 0.009) and lower basal septal Ea velocities (1.4 ± 0.8
cm/s for class I vs. 3.8 ± 2 cm/s) when compared to the rest
of the non-obstructive HC patients. Because of the low
number of severely symptomatic patients in non-obstruc-
tive group, no further statistical analyses were performed.
Discussion
In the present study, we found that NYHA functional class
of the HC patients correlated with various echocardio-
graphic and clinical parameters such as age, left atrium
diameter, E wave deceleration time (EDt), LV lateral
mitral annular systolic tissue Doppler velocity (LMSa),
and LV outflow obstruction. Besides these findings, we
have shown that EDt, LMSa, and LV outflow obstruction
independently predict the presence of severe heart failure
symptoms in HC patients with sinus rhythm and normal
LV ejection fraction. LMSa is lower and EDt is longer in
patients with higher NYHA class which reflects disease
severity.
In HC patients, limiting symptoms of exertional dyspnea
typically occur in the presence of preserved systolic func-
tion and a non-dilated LV [1,4]. Symptoms appear to be
caused mainly by diastolic dysfunction [5-8], myocardial
ischemia [9-15], outflow obstruction associated with
mitral regurgitation [16,17], and atrial fibrillation [18].
On the other side, Chikamori and colleagues suggest that
there are different mechanisms of exercise limitation in
hypertrophic cardiomyopathy: in patients with a left ven-
tricular outflow gradient at rest, the main determinants of
exercise limitation were impaired left ventricular and left
atrial systolic performance; in those without a gradient,
however, diastolic function at rest was a more important
factor in the limitation of exercise performance [26]. In
our study, non-obstructive severely symptomatic patients
(n = 3) had significantly larger left atrium diameters and
lower basal septal Ea velocities when compared with the
rest of the non-obstructive patients, but because of the
Comparison of left ventricle lateral mitral annular systolic tis- sue Doppler velocity (LMSa) of severely symptomatic HC  patients with the rest of the group (p < 0.002) Figure 2
Comparison of left ventricle lateral mitral annular systolic tis-
sue Doppler velocity (LMSa) of severely symptomatic HC 
patients with the rest of the group (p < 0.002).
Comparison of E wave deceleration time of severely sympto- matic HC patients with the rest of the group (p < 0.001) Figure 1
Comparison of E wave deceleration time of severely sympto-
matic HC patients with the rest of the group (p < 0.001).Trials 2008, 9:11 http://www.trialsjournal.com/content/9/1/11
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low number of patients, we can not make any further
comments. In view of all these information, it still seems
to be controversial whether or not left ventricular diastolic
pressure and function at rest are major determinants of
exercise capacity in hypertrophic cardiomyopathy, and
the true mechanism of exercise limitation remains
unclear.
Doppler echocardiographic evaluation of trans-mitral LV
filling velocities is widely used to assess LV diastolic func-
tion. However, most studies [27,28] have failed to show
significant correlations between Doppler- derived trans-
mitral flow velocities and exercise capacity in patients
with HC. Conventional echocardiographic Doppler
indexes may be unreliable for assessment of LV diastolic
function in such patients, probably because of their
dependence on loading conditions [29-31]. In our study,
EDt was an independent predictor of severe symptoms
but its value may be limited because of its dependence in
loading conditions, and as a result tissue Doppler varia-
bles and LV outflow obstruction may be more valuable in
that respect.
Similar to our findings, the association between tissue
Doppler variables and heart failure symptoms were dem-
onstrated in several trials. Tissue Doppler derived indexes
were found to be correlated with exercise capacity and
NYHA functional class in HC patients [32,33], but these
studies have evaluated the relation between symptoms
and diastolic tissue Doppler variables. In our study, for
the first time we have demonstrated that systolic tissue
Doppler variables are also of importance in respect of pre-
dicting heart failure symptoms. The decreased LMSa in
symptomatic HC patients may be explained with progres-
sive remodelling and/or fibrosis of left ventricle over time
and may be of value as a predictor of occult systolic dys-
function and impending heart failure symptoms.
We did not observe statistically significant differences in
systolic and diastolic TD velocities of left and right ventri-
cle (except lateral mitral Ea) between HC patients with
and without LV outflow obstruction. These findings were
in accordance with previously published studies [34,35].
Assessment of symptom severity may be highly subjective,
encumbered by the heterogeneous presentation of the
patients. So, EDt and LMSa may guide the clinician in
deciding the severity of the disease and in making the
decision for further invasive therapies. Patients with LV
outflow obstruction, longer EDt, and lower LMSa seem to
be under risk of clinical deterioration as they have more
severe symptoms, but this data will have to be validated
with further prognostic studies.
The study was conducted at a tertiary referral cardiac hos-
pital; as a result high prevalence of severe heart failure
symptoms (20%) and LV outflow obstruction (50%) were
observed.
The small number of HC patients is a weakness of our
study, and also we can not exclude the possibility that
some patients may develop advanced symptoms of heart
failure later in life. NYHA classification, as a subjective
measurement of functional disability, may not always
reflect functional status accurately in HC patients, but in
previous studies, metabolic stress testing in a large HC
cohort showed peak oxygen consumption to be signifi-
cantly related to NYHA class [36].
Conclusion
For HC patients, LMSa, EDt and LV outflow obstruction
are independent predictors of heart failure symptoms.
These findings suggest that diastolic dysfunction deter-
mined with EDt, occult systolic dysfunction which is
detected with tissue Doppler analysis, and afterload
increase as result of LV outflow obstruction may be the
main echocardiographic factors affecting symptomatic
status in HC patients with sinus rhythm and normal systo-
lic function.
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